BioSpace News Archive

Biotech Bay

Money on the Move: July 21 – 27, 2021

A quick overview of life science companies scooping up some summer spending money this week.

July 28, 2021
·
3 min read
·
Kate Goodwin
Self-Destructing Malaria-Spreading Mosquitos? How Genetic Engineering Could Make It So

A breakthrough study has found that altering the genetic makeup of malaria-carrying mosquito species could be the key to stopping the spread of the malaria virus and finally eradicating the disease.

July 28, 2021
·
2 min read
·
Vanessa Doctor, RN
Deals

$2.5B Teneobio Deal Complements Amgen’s Core and Capabilities

Amgen will gain Teneobio’s proprietary bispecific and multispecific antibody technologies, which have the potential to target multiple diseases across Amgen’s core therapeutic areas.

July 28, 2021
·
3 min read
·
Alex Keown
Business

AbbVie/Calico Innovation Engine Will Keep On Chugging Against Age-Related Diseases

The extension will see a new investment of nearly $1 billion, which AbbVie and Calico will split down the middle.

July 28, 2021
·
2 min read
·
Heather McKenzie
Job Trends

Life Sciences Companies Throwing Money into Facility Expansions and Jobs

There has been a flurry of expansion activity in the life sciences industry as biopharma and diagnostic companies expand manufacturing sites. Here’s a look.

July 28, 2021
·
4 min read
·
Mark Terry
Genetown

JAMA Paper Withdrawal Adds One More Layer to Aduhelm Controversy

Biogen reportedly withdrew a paper it had submitted to the medical journal JAMA after the publication requested edits before publication. It’s standard for a technical journal to request edits, but it is the nature of the edits—and in this case, the nature of the study— that raises questions.

July 28, 2021
·
3 min read
·
Mark Terry
Drug Development

GSK Posts Strong Q2 as it Moves toward 2022 Demerger

The company’s pipeline was strengthened in the second quarter with three strategic collaborations in immuno-oncology, immuno-neurology, and HIV.

July 28, 2021
·
3 min read
·
Alex Keown
Business

Blueprint, MD Anderson Cancer Center Accelerate Research Partnership To Develop Cancer Therapies

The research will focus on accelerating the capacities of BLU-222, an investigational therapy that Blueprint designed to target cyclin-dependent kinase 2 (CDK2).

July 28, 2021
·
2 min read
·
Vanessa Doctor, RN
Business

IMIDomics, IgGenix and neuro42 Close Series A Rounds Worth Millions

Three companies, including two biotech companies and one drug discovery company, announced yesterday the successful closing of Series A financing, with IMIDomics taking the lead.

July 28, 2021
·
2 min read
·
Brandon May
Job Trends

Deep Genomics is Rewriting RNA for Powerful Therapeutics with $180M Series C

“For the first time in history, medicine has become information.” That’s the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey.

July 28, 2021
·
3 min read
·
Kate Goodwin